Compare GSK plc (GSK) vs Moody's Corporation (MCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Moody's Corporation — how do they compare? GSK plc trades at $52.77 (market cap $101.34B), while Moody's Corporation trades at $516.13 (market cap $88.12B). The key difference: GSK plc is the larger of the two by market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | MCO | |
|---|---|---|
Market Cap | $101.34B | $88.12B |
Sector | Health | Financials |
52-Week High | $61.18 | $539.61 |
52-Week Low | $36.20 | $412.23 |
Enterprise Value | $121.95B | $93.92B |
Dividend Yield | 3.49% | 0.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
MCO trades at $515, up 4.1% today, near its 52-week high. The stock shows strong technical momentum with bullish moving averages and support at $501. Fundamentally, Moody's delivered three consecutive earnings beats with Q1 2026 EPS of $4.33 beating expectations. Revenue grew to $7.72B in 2025 with exceptional profitability margins (net margin 31.69%, ROE 74.54%). Recent developments include AI integration initiatives and a $1.03 dividend payment scheduled for June 2026.
Outlook remains positive with analyst consensus target at $539.40 (4.7% upside) and 56% buy ratings. Key opportunities include AI-driven growth and sustained debt issuance demand. Risks include high valuation multiples (P/E 36.19) and sensitivity to credit cycle changes. Cash flow trends show volatility with 2026 projection of -$670M net cash flow requiring monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →
